D. E. Shaw & Co. Inc. Sells 41,179 Shares of Rhythm Pharmaceuticals Inc (RYTM)
D. E. Shaw & Co. Inc. lessened its stake in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) by 78.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,982 shares of the company’s stock after selling 41,179 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Rhythm Pharmaceuticals were worth $295,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of RYTM. Great West Life Assurance Co. Can purchased a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at approximately $68,000. Legal & General Group Plc boosted its holdings in Rhythm Pharmaceuticals by 46.6% in the 3rd quarter. Legal & General Group Plc now owns 2,675 shares of the company’s stock valued at $78,000 after purchasing an additional 850 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in Rhythm Pharmaceuticals in the 3rd quarter valued at approximately $280,000. Alliancebernstein L.P. boosted its holdings in Rhythm Pharmaceuticals by 74.0% in the 3rd quarter. Alliancebernstein L.P. now owns 12,700 shares of the company’s stock valued at $370,000 after purchasing an additional 5,400 shares in the last quarter. Finally, TD Asset Management Inc. boosted its holdings in Rhythm Pharmaceuticals by 5.5% in the 4th quarter. TD Asset Management Inc. now owns 15,359 shares of the company’s stock valued at $413,000 after purchasing an additional 797 shares in the last quarter. Hedge funds and other institutional investors own 92.00% of the company’s stock.
A number of equities research analysts have weighed in on RYTM shares. LADENBURG THALM/SH SH started coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 13th. They issued a “buy” rating and a $43.00 price objective on the stock. Zacks Investment Research raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 21st. Cowen reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Rhythm Pharmaceuticals in a report on Friday, March 8th. BidaskClub raised Rhythm Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. Finally, ValuEngine raised Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Rhythm Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $39.00.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.17). As a group, equities research analysts forecast that Rhythm Pharmaceuticals Inc will post -3.01 earnings per share for the current fiscal year.
In other news, CEO Keith Michael Gottesdiener sold 15,779 shares of the business’s stock in a transaction that occurred on Wednesday, January 23rd. The stock was sold at an average price of $30.05, for a total transaction of $474,158.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 65,637 shares of company stock worth $1,971,840 in the last three months. Corporate insiders own 4.93% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/d-e-shaw-co-inc-sells-41179-shares-of-rhythm-pharmaceuticals-inc-rytm/2965345.html.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Featured Article: What is the return on assets (ROA) ratio?
Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM).
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.